Safety and Efficacy Trial Evaluating the Use of SR34006 in the Treatment of Deep Vein Thrombosis (DVT)
Status:
Completed
Trial end date:
2005-09-01
Target enrollment:
Participant gender:
Summary
Patients who have deep vein thrombosis (blood clot in the leg) will be treated in this study.
The purpose of the study is to compare the safety and effectiveness of a new injectable
anticoagulant (blood thinning) drug administered once each week, SanOrg34006, with the
standard way of treating deep vein thrombosis. The standard treatment includes injections or
infusions of an anticoagulant drug (Unfractionated Heparin or low molecular weight heparin)
for about a week, followed by vitamin K antagonist (VKA) anticoagulant tablets (warfarin or
acenocoumarol) which are taken by mouth. Eligible patients will be assigned to treatment with
either SanOrg34006 or the combination of Unfractionated Heparin or low molecular weight
heparin plus a VKA (warfarin or acenocoumarol) by random chance. Treatment will be known to
both patients and their doctors.
Phase:
Phase 3
Details
Lead Sponsor:
Sanofi
Treatments:
Calcium heparin Heparin Idraparinux SANORG 34006 Vitamin K